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Objectives The purpose of this study was to estimate rates and identify predictors of inpatient complications and 30-day
readmissions, as well as repeat hospitalization rates for arrhythmia recurrence following atrial fibrillation (AF)
ablation.
Background AF is the most common clinically significant arrhythmia and is associated with increased morbidity and mortal-
ity. Radiofrequency or cryotherapy ablation of AF is a relatively new treatment option, and data on post-
procedural outcomes in large general populations are limited.
Methods Using data from the California State Inpatient Database, we identified all adult patients who underwent their
first AF ablation from 2005 to 2008. We used multivariable logistic regression to identify predictors of complica-
tions and/or 30-day readmissions and Kaplan-Meier analyses to estimate rates of all-cause and arrhythmia
readmissions.
Results Among 4,156 patients who underwent an initial AF ablation, 5% had periprocedural complications, most com-
monly vascular, and 9% were readmitted within 30 days. Older age, female, prior AF hospitalizations, and less
hospital experience with AF ablation were associated with higher adjusted risk of complications and/or
30-day readmissions. The rate of all-cause hospitalization was 38.5% by 1 year. The rate of readmission for
recurrent AF, atrial flutter, and/or repeat ablation was 21.7% by 1 year and 29.6% by 2 years.
Conclusions Periprocedural complications occurred in 1 of 20 patients undergoing AF ablation, and all-cause and arrhythmia-
related rehospitalizations were common. Older age, female sex, prior AF hospitalizations, and recent hospital
procedure experience were associated with a higher risk of complications and/or 30-day readmission after AF
ablation. (J Am Coll Cardiol 2012;59:143–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.068The prevalence of atrial fibrillation (AF) among U.S. adults
is expected to rise from 2.3 million to at least 5.6 million by
2050, with an increasing burden of medical costs (1,2).
Catheter ablation, a newer treatment option for AF that
uses radiofrequency or cryotherapy to electrically isolate the
pulmonary veins and ablate arrhythmia foci, is increasing in
use. Randomized studies have suggested that AF ablation
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accepted August 29, 2011.may decrease arrhythmia burden and improve quality of life,
and observational studies have suggested that ablation may
be associated with lower ischemic stroke and death rates (3).
See page 150
Procedural complications have been reported to affect
between 1% and 8% of patients undergoing AF ablation at
experienced academic hospitals (4,5) and 7% to 10% among
Medicare beneficiaries treated in centers of varying types
(6). However, relatively little is known about use of AF
ablation and complication rates in contemporary patient
cohorts across the age spectrum treated in community
settings. Furthermore, the frequency of rehospitalizations
and repeat ablation procedures among unselected patients is
not well understood.
Using data from the Healthcare Utilization Project California
State Inpatient Database (7), we characterized trends in AF
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tions, and repeat hospitalizations
in a large, diverse contemporary
population. We also sought to eval-
uate predictors of poor outcomes,
including procedural complications
and 30-day rehospitalizations.
Methods
Catheter ablation and arrhythmia. The California State
Inpatient Database, from Healthcare Utilization Project
(Agency for Healthcare Research and Quality), contains
administrative data for all discharges from nonfederal hos-
pitals in the state plus an encrypted linking variable to track
hospitalizations of the same patient over time (7). We
identified patients who received an initial AF ablation
procedure between January 1, 2005, and November 31,
2008, by searching for discharges with a principal diagnosis
of AF (International Classification of Diseases-9th Edition
[ICD-9] 427.31) and a concurrent catheter ablation proce-
dure code (ICD-9 37.34). We excluded patients with
secondary diagnosis codes for atrial flutter, Wolff-
Parkinson-White syndrome, nonparoxysmal atrioventricu-
lar nodal tachycardia, paroxysmal supraventricular tachycar-
dia, paroxysmal ventricular tachycardia, and ventricular
premature beats. We also excluded patients with diagnostic
or procedural codes indicating implantation of a pacemaker
or implantable cardioverter-defibrillator during the index
admission (to exclude those undergoing atrioventricular
node ablation) and patients undergoing open surgical abla-
tion (Online Table A1). Patients were excluded from this
analysis if they had received an AF ablation in 2004 to
include only patients who presumably had their first AF
ablation during the study period.
Patient comorbidities. Comorbid conditions were identi-
fied based on secondary diagnosis codes for coronary artery
disease, heart failure, cerebrovascular disease, renal disease,
hypertension, diabetes, valvular heart disease, and lung
disease during the index AF ablation hospitalization and a
concurrent “present on admission” indicator (Online Table
A2). In addition, patients were classified as having coronary
artery disease, heart failure, cerebrovascular disease, or lung
disease if they had been hospitalized during the year before
the index procedure with a primary diagnosis of these
conditions. Patients were classified as having chronic renal
disease, hypertension, diabetes, valvular heart disease, lung
disease, or cancer if they had been hospitalized during the
year before the index procedure with the relevant ICD-9
code as either the primary or a secondary diagnosis (Online
Table A2).
The database does not provide detail to characterize the
type or duration of AF. Therefore, we used the number of
AF hospitalizations as a proxy to account for disease
Abbreviations
and Acronyms
AF  atrial fibrillation
ICD-9  International
Classification of Diseases-
9th Editionseverity, defined as the number of hospitalizations with AF ain the primary diagnostic position during the year before
index ablation.
Outcomes. Acute procedural complications included car-
diac perforation and/or tamponade, pneumothorax, hemo-
thorax, procedure-related stroke, transient ischemic attack,
vascular access complication (consisting of hemorrhage/
hematoma, vascular complication requiring surgical repair,
and accidental puncture), and in-hospital death (Online
Table A2). Procedural complications were identified using
secondary diagnoses coded during the index AF ablation
admission.
We estimated rates of all-cause and cause-specific 30-day
rehospitalizations. Cause-specific reasons for 30-day read-
missions included procedural complications and primary
diagnoses of AF or atrial flutter (Online Table A3). Long-
term outcomes of interest included hospitalization for any
cause and admission for arrhythmia recurrence at any time
after ablation through the end of the study period. Arrhyth-
mia recurrence was defined as a repeat hospitalization with
a primary diagnosis of AF or atrial flutter or a repeat
hospitalization with a procedure code for catheter ablation.
Statistical analysis. Categorical data are presented as fre-
quencies and percentages; continuous data are presented as
mean  SD. Univariate comparisons were performed using
t tests for continuous variables and chi-square tests for
categorical and binary variables. Multivariable logistic re-
gression with generalized estimating equations (to account
for within-hospital clustering) were used to identify predic-
tors of inpatient complication and/or 30-day all-cause
rehospitalization. Patient demographics (age, sex, and race/
ethnicity), primary payer, comorbid conditions, number of
AF hospitalizations during the prior year, and recent hos-
pital procedure experience were included in the multivari-
able model. Recent procedure experience was defined as the
number of cases completed at a given center during the 12
months before each index AF ablation divided into quartiles
for comparison.
We used Kaplan-Meier analyses to estimate all-cause
readmission and arrhythmia rehospitalization rates. For the
readmission analysis, patients were censored at the end of
the study period (December 31, 2008). For the arrhythmia
rehospitalization analysis, patients were censored if they
died during a hospitalization or at the end of the study
period. Ascertainment of death was limited to those that
occurred within a California hospital because the database
cannot be linked with the National Death Index.
A value of p  0.05 was considered statistically signifi-
ant. All analyses were performed using Stata version 11.0
StataCorp LP, College Station, Texas).
esults
e identified 4,156 patients who received an initial AF
blation in California between January 1, 2005, and No-
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January 10, 2012:143–9 Outcomes After Atrial Fibrillation Ablationvember 31, 2008. The number of initial procedures almost
doubled from 684 cases in 2005 to 1,332 cases in 2008; the
mean annual volume of AF ablations per hospital was 15.4
throughout the study period. A total of 98 unique hospitals
performed AF ablations during the study period; the num-
ber of hospitals increased from 60 in 2005 to 77 in 2008. In
this sample, mean patient age was 61.7 years; hypertension
Baseline Characteristics for Patients With/With(Periprocedural and/or 30-Day R admission) AfTable 1 B seline Characteristic for Patien(Periprocedural and/or 30-Day Rea
Variable
All P
(N 
Mean age, yrs 61.7
Age group, yrs*
18–44 310
45–54 778
55–64 1,327
65–84 1,080
75–84 512
85 97
Age 65 yrs*† 1,689
Sex*†
Male 2,81
Female 1,21
Primary payer†
Medicare 1,51
Private insurance 2,41
Race/ethnicity
White 3,35
Black 6
Hispanic 24
Other/missing 49
Year
2005 68
2006 94
2007 1,20
2008 1,32
AF hospitalizations during year prior to ablation‡
0 3,28
1 67
2 14
3 5
Coronary artery disease* 60
Heart failure* 38
Renal disease* 13
Cerebrovascular disease 5
Diabetes mellitus* 51
Valvular disease* 51
Hypertension* 2,09
Lung disease* 17
Mean no. of procedural experiences (SD)§ 54.32
Quartile 1 (highest) 1,037
Quartile 2 1,015
Quartile 3 1,013
Quartile 4 (lowest) 1,091
Values are mean SD or n (%). *Significant predictors of 30-day read
the number of hospitalizations with atrial fibrillation (AF) in the prima
and n  3 for 6 AF hospitalizations. §Procedural experience is the n
preceding each index case.(50.3%) and coronary artery disease (14.7%) were the mostcommon comorbidities (Table 1). Most patients had not
been hospitalized primarily for AF during the year before
ablation (79.1%). Recent hospital procedural experience
during the preceding 12 months varied from 7.0  4.4
procedures in the lowest quartile to 136.9  27.8 in the
highest quartile. The observation time (from time of initial
AF ablation through December 31, 2008) was a median
omplicationsF Ablationth/Wi h ut Complications
ion) After AF Ablation
s
)
No Complications
(n  3,591)
Complications
(n  565) p Value
.0 61.2 12.0 64.7 11.8 0.001
0.001
286 8.0 24 4.3
.7 693 19.3 85 15.0
.9 1,157 32.2 170 30.1
.0 912 25.4 168 29.7
.3 415 11.6 97 17.2
8 77 2.1 20 3.5
.6 1,404 39.1 285 50.4 0.001
0.001
) 2,484 (69.2) 335 (59.3)
) 997 (27.8) 222 (39.3)
0.001
) 1,251 (34.8) 262 (46.5)
) 2,146 (59.8) 270 (47.8)
0.360
) 2,896 (80.7) 457 (80.9)
57 (1.6) 10 (1.8)
203 (5.7) 40 (7.1)
) 189 (5.3) 33 (5.8)
0.348
) 577 (16.1) 107 (18.9)
) 815 (22.7) 129 (22.8)
) 1,046 (29.1) 160 (28.3)
) 1,153 (32.1) 169 (29.9)
0.001
) 2,873 (80.0) 416 (73.6)
) 563 (15.7) 108 (19.1)
120 (3.3) 26 (4.6)
35 (1.0) 15 (2.7)
) 512 (14.3) 97 (17.2) 0.069
306 (8.5) 82 (14.5) 0.001
106 (3.0) 33 (5.8) 0.001
45 (1.3) 12 (2.1) 0.098
) 437 (12.2) 81 (14.3) 0.147
) 429 (12.0) 81 (14.3) 0.108
) 1,776 (49.5) 314 (55.6) 0.007
137 (3.8) 35 (6.2) 0.008
.2 55.8 53.8 44.6 48.0 0.001
.0 933 26.0 104 18.4
.4 885 24.6 130 23.0
.4 858 23.9 155 27.4
.2 915 25.5 176 31.2
only. †Significant predictors of inpatient outcomes only. ‡Defined as
ostic position; for full cohort, n  31 for 3, n  11 for 4, n  5 for 5,
of AF ablations completed at a given hospital during the 12 monthsout Cter As Wi
dmiss
atient
4,156
 12
 7.5
 18
 31
 26
 12
 23
 40
9 (67.8
9 (29.3
3 (36.4
6 (58.3
3 (80.7
7 (1.6)
3 (5.9)
3 (11.9
4 (16.5
4 (22.7
6 (29.0
2 (31.8
9 (79.1
1 (16.2
6 (3.5)
0 (1.2)
9 (14.7
8 (9.3)
9 (3.3)
7 (1.4)
8 (12.5
0 (12.3
0 (50.3
2 (4.1)
 53
 25
 24
 24
 26
mission
ry diagn(interquartile range) of 1.53 years (0.78 to 2.62).
0
3
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Outcomes After Atrial Fibrillation Ablation January 10, 2012:143–9Inpatient complications occurred in 5.1% (n  211) of
AF ablations and did not vary according to study year.
Vascular complications, primarily bleeding-related events,
accounted for more than half of all complications (Table 2).
One patient died during the index admission. Length of
stay was 1.46  1.96 days for those without complications
and 3.42  3.44 days for those with complications (p 
.001). Within 30 days of index hospitalization, 9.4% (n 
90) of patients discharged alive were rehospitalized. AF or
trial flutter accounted for 26.9% of readmissions (n 105),
and procedural complications accounted for another 19.5%
of readmissions (n  76) (Table 2).
Age, sex, primary payer, heart failure, hypertension,
chronic renal disease, lung disease, number of AF hospital-
izations during the prior year, and procedure volume quar-
tile were univariate predictors of inpatient complications
and/or 30-day rehospitalization (p  0.05 for each) (Table 1).
In the multivariable analyses, female sex (odds ratio [OR]:
1.38 compared with males; 95% confidence intervals [CI]:
1.13 to 1.69) and number of AF hospitalizations during
prior year (OR: 1.19 for each additional admission; 95% CI:
1.05 to 1.35) were significant predictors of the outcome
(Table 3). The odds of inpatient complication and/or
30-day readmission increased in a stepwise fashion with
increasing patient age, up to age 85 years (Table 3). Less
hospital experience with AF ablation was also a significant
predictor of the outcome, with a 57% increase in the odds of
the outcome in the lowest compared with the highest
quartile (Table 3). Every 5-U increase in the number of
procedures completed during the prior 12 months decreased
the odds of the outcome by 2% (OR: 0.98; 95% CI: 0.97 to
Outcomes During and After Hospitalizationfor AF AblationTable 2 Outcomes During and After Hospitalizationfor AF Ablation
Inpatient Complication
or Rehospitalization
Patients Undergoing
AF Ablation
(N  4,156)
Any complication 211 (5.1)
Vascular complication 110 (52.1)
Hematoma/hemorrhage only 93 (44.1)
Perforation/tamponade 104 (49.3)
Stroke 10 (4.7)
Pneumothorax/hemothorax 4 (1.9)
Transient ischemic attack 3 (1.4)
Death 1 (0.5)
30-day rehospitalization
All-cause 390 (9.4)
AF/atrial flutter 105 (26.9)
Any procedural complication 76 (19.5)
Pneumothorax/hemothorax 3 (0.8)
Vascular complication 45 (11.5)
Perforations/tamponade 12 (3.1)
Acute stroke* 19 (4.9)
Death 9 (2.3)
Values are n (% of complications or 30-day rehospitalizations). *Acute strokes include hemorrhagic
and ischemic events plus transient ischemic attacks.
Abbreviation as in Table 1.0.99).In long-term follow up, 1,816 patients were readmitted
after AF ablation for any reason. At 1 year, 61.5% of
patients were free of hospital admission (95% CI: 59.9% to
63.1%) (Fig. 1). A total of 1,022 patients were rehospital-
ized for arrhythmia recurrence or repeat ablation. At 1 year,
78.3% (95% CI: 76.9% to 79.6%) of patients were free of
readmission for recurrent arrhythmia or repeat ablation; at 2
years, 70.4% (9% CI: 68.7% to 72.0%) of patients were free
of rehospitalization for recurrent arrhythmia or repeat ab-
lation (Fig. 2). Among the 4,156 recipients of an initial AF
ablation, 17.4% received additional ablation; 682 patients
received 1 additional ablation, 36 received 2 additional
ablations, 3 received 3 additional ablations, and 3 received 4
additional ablations during the study period.
Discussion
In a large contemporary cohort of patients who underwent
AF ablation in California, 5% of patients experienced a
periprocedural complication and almost 10% were rehospi-
talized with 30 days. By 1 year, 22% of patients were
rehospitalized for arrhythmia recurrence or repeat ablation
and almost 40% were rehospitalized for any reason.
Multivariable Analysis for Predictors of InpatientComplications Plus All-Cause 30-Day Rehospi alizationsTable 3 Mu tivariable Analysis for Predictors of InpatientComplications Plus All-Cause 30-Day Rehospitalizations
Variable Odds Ratio
95% Confidence
Interval
Age group, yrs
18–44 1.00 (reference) N/A
45–54 1.52 0.94–2.45
55–64 1.77 1.13–2.79
65–74 1.86 1.09–3.15
75–84 1.95 1.10–3.46
85 1.72 0.82–3.61
Female 1.38 1.13–1.69
Race/ethnicity* 1.10 0.86–1.40
Primary payer† 0.83 0.60–1.15
Procedural experience‡
Quartile 1 (highest) 1.00 (reference) N/A
Quartile 2 1.38 1.04–1.82
Quartile 3 1.64 1.25–2.15
Quartile 4 (lowest) 1.56 1.19–2.05
Year 0.94 0.86–1.03
AF hospitalizations§ 1.19 1.05–1.35
Heart failure 1.33 0.99–1.80
Coronary artery disease 1.03 0.78–1.34
Hypertension 0.99 0.81–1.21
Diabetes mellitus 0.93 0.71–1.23
Cerebrovascular disease 1.35 0.70–2.60
Renal disease 1.43 0.92–2.22
Valvular disease 0.85 0.65–1.13
Lung disease 1.21 0.81–1.81
*All others/missing compared with white. †Private insurance compared with Medicare. ‡Defined
as the number of AF ablations completed at a given hospital during the 12 months preceding each
index ablation. §Defined as the number of hospitalizations during the year before index ablation
with AF in the primary diagnostic position; the odds ratio represents the increase per 1 U increase
in AF hospitalizations.
N/A  not applicable; other abbreviation as in Table 1.
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January 10, 2012:143–9 Outcomes After Atrial Fibrillation AblationFigure 1 Kaplan-Meier Curve for All-Cause Readmissions After Initial Atrial Fibrillation Ablation
One year: 61.5% (95% confidence interval: 59.9% to 63.1%) of patients were free of all-cause hospital admission. Reference lines are at 12 and 24 months.Figure 2 Kaplan-Meier Curve for Hospitalization for Arrhythmia Recurrence* or Repeat Ablation After Initial Atrial Fibrillation Ablation
One year: 78.3% (95% confidence interval: 76.9% to 79.6%) of patients were free of hospitalization for recurrent arrhythmia or repeat ablation. Two years: 70.4% (95%
confidence interval: 68.7% to 72.0%) of patients were free of hospital admission for recurrent arrhythmia or repeat ablation. *Recurrent arrhythmia is defined as hospi-
talization for atrial fibrillation or atrial flutter. Reference lines are at 12 and 24 months.
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Outcomes After Atrial Fibrillation Ablation January 10, 2012:143–9Periprocedural complication rates following AF ablation
have ranged from 1% to 8% in smaller studies of high-
volume centers (4,9), and the complication rate was 9.1% in
a study of Medicare beneficiaries (6). The periprocedural
complication rate of 5.1% in this study is derived from a
large contemporary cohort that is more representative of the
general AF population than prior estimates from selected
patient cohorts (6,10).
Policymakers have begun to focus on 30-day readmission
rates as a potential marker of quality of care. Prior studies of
AF ablation have not reported 30-day readmission rates,
which we found to be 10% overall (most commonly for AF
and atrial flutter) and 12.1% among patients age 65 years
and older. This readmission rate after AF ablation is lower
than the 14.6% 30-day readmission rate of Medicare ben-
eficiaries after percutaneous coronary intervention (8) and
lower than the 20.1% readmission rate of Medicare benefi-
ciaries after heart failure hospitalization (11), although still
high for an elective procedure.
Hospitalization for recurrent arrhythmia or repeat abla-
tion occurred frequently, affecting 22% of patients at 1 year
and 30% of patients at 2 years (Fig. 2). Randomized
controlled trials have reported AF recurrence in 13% to 44%
of AF ablation recipients (12,13), and a worldwide survey of
centers offering AF ablation reported recurrence in 48% to
57% of recipients at a median of 12 months’ follow-up (4).
The estimate in our study was at the lower end of the
reported range because the database does not capture
outpatient or asymptomatic recurrence. Our findings were
therefore consistent with previous studies that observed that
AF ablation has limited success in preventing arrhythmia
recurrence over longer-term follow-up (4). We further
demonstrated that these recurrences were often severe
enough to result in costly hospitalizations.
Slightly20% of patients in this cohort of unselected AF
ablation recipients received multiple ablations, which is
lower than the rates reported from specialized centers. The
worldwide survey mentioned previously reported that more
than 25% of patients received repeat ablations within a
median follow-up time of 12 months (4). The difference
between our findings and those from specialized centers
may be due to a more aggressive approach of specialty
centers in treating recurrent arrhythmias. Alternatively,
specialized centers may select patients who are healthier or
who have disease that is more amenable to ablation, making
repeat ablation more attractive.
The increased procedural risk for women undergoing AF
ablation was consistent with patterns seen in other cardiovas-
cular procedures. Women undergoing percutaneous coronary
intervention have more than a 2-fold higher risk of vascular
complications than men (14–16), perhaps because of smaller
body size or higher levels of anticoagulation among women
(17). However, a report on risk factors for bleeding with
unfractionated heparin found that female sex remained a risk
factor after controlling for weight, heparin dose, and activated
partial thromboplastin time, suggesting that mechanisms otherthan medication dosing could account for increased bleeding
risk in women (18).
We found that that recent procedural experience with AF
ablation was inversely related to complication rates, which was
consistent with the general observation that higher hospital
volume has been associated with better outcomes for various
procedures (19–21) and medical conditions (22). Our measure
of procedural experience differed from the methods used to
estimate hospital volume in prior publications in that we
assessed the number of procedures performed in the prior 12
months as the metric, rather than the average procedure
volume over several years. This measure of recent experience
captured the effect of the “learning curve” for new procedures
such as AF ablation. Our finding of better outcomes among
patients treated at centers with more procedural experience in
the prior 12 months suggested that higher procedure volumes
are needed to gain proficiency, maintain proficiency, or both.
Study limitations. The administrative data used in this
analysis lack the detail that is available in trials and registries.
Physician characteristics and full assessment of comorbidities
(i.e., including outpatient diagnoses) were unavailable for the
analyses. This limitation is counterbalanced by the larger
sample size and the absence of reporting bias introduced by
selective publication of results from specialized centers. Data
about procedural technique, medication use, and type of AF
(e.g., paroxysmal or persistent) were unavailable. We did,
however, use the number of AF hospitalizations during the
year before index ablation as a proxy for disease severity.
The patients in this study were representative of the general
AF ablation population, but certain limitations in our cohort
assembly should be noted. We identified patients who had
their “first” procedure between 2005 and 2008, looking back
through 2004. Some patients may have had procedures before
2004. Given the smaller number of AF ablations completed in
earlier years, however, the number of misclassified patients
should be small. Patients who had pacemakers placed before
the index hospitalization and who may have had an atrioven-
tricular junction ablation were not excluded.
Our study did not include a comparison of patients with
AF treated with antiarrhythmic drugs. We found high
rehospitalization rates following ablation, but patients with
AF treated with other methods may have similar or higher
rates. Also, 18% of patients without reported complications
were hospitalized for 2 or more days, some of whom may
have had a complication that was not coded in the hospital
discharge abstract. Finally, the database could not be linked
with the National Death Index; therefore, we could not
accurately assess mortality late after the procedure, although
we could detect all deaths during the index admission.
Conclusions
AF ablation is a newer treatment option that is being used
with increasing frequency. In this large, unselected cohort of
AF ablation recipients, 1 in 20 patients experienced a
periprocedural complication and almost 1 in 10 were rehos-
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sex, prior AF hospitalizations, and recent hospital procedure
experience were factors associated with a high risk of
complications and/or 30-day rehospitalization after AF
ablation. Future investigations should be directed at iden-
tifying ways to decrease procedural complication rates,
arrhythmia recurrence, and readmissions.
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